Lexicon Pharmaceuticals, Inc.: Form 10-K for the period ended Dec 31, 2024
Filed with the SEC on Mar 7, 2025 and accepted by EDGAR at Mar 7, 2025, 16:02 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2024-01-01 to 2024-12-31 | $6.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2024-01-01 to 2024-12-31 | $616.0k | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 12 months2024-01-01 to 2024-12-31 | $84.5m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2024-01-01 to 2024-12-31 | $143.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2024-01-01 to 2024-12-31 | −$197.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2024-01-01 to 2024-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2024-01-01 to 2024-12-31 | −$200.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2024-01-01 to 2024-12-31 | −$0.63 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2024-01-01 to 2024-12-31 | −$0.63 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2024-01-01 to 2024-12-31 | 320,031,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2024-01-01 to 2024-12-31 | −$178.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2024-01-01 to 2024-12-31 | $1.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2024-01-01 to 2024-12-31 | $1.7m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2024-12-31 | $66.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-12-31 | $246.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-12-31 | $298.4m | us-gaap:Assets |
| Current liabilities | At period end2024-12-31 | $45.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-12-31 | $152.5m | us-gaap:Liabilities |
| Long-term debt | At period end2024-12-31 | $100.3m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2024-12-31 | $145.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001062822-25-000013. Last ingested by Listed: Nov 5, 2026, 16:37 ET. Listed shows no prices and gives no investment advice.